• 한국전자통신학회논문지
• /
• 제13권3호
• /
• pp.579-586
• /
• 2018

빅데이터에 대한 관심이 증가하면서 데이터로부터 의미 있는 정보의 추출 및 예측은 중요한 연구분야가 되고 있다. 본 연구에서는 신약개발과정에서 필요한 후보약물의 약리적인 활성을 분석하기 위한 데이터를 획득하고 이를 기반으로 의미 있는 예측 분석을 하고자 한다. 신약개발과정에서 대사반응 된 신약후보물질의 약리적인 활성 연구는 신약개발 성공률을 높이기 위해 필요한 단계이다. 본 연구에서, 약용 후보물질의 체내 효소 반응 유무를 예측하기 위해, 유사도 모델들을 적용 분석하였다. 유사도 모델의 군집별 특성을 반영하여 13개의 모델을 선택하여 효소 반응 예측을 수행하였다. 이들 모델들을 민감도와 AUC를 기반으로 비교 평가하였다. 평가 모델들 중, 효소 사이의 반응성을 예측하는데 있어서 Simpson coefficient 모델이 가장 좋은 성능을 보였다. 분석된 유사도 모델 전체를 웹 서비스로 구축하였다. 제안된 모델은 반응정보의 추가에 동적으로 대응 할 수 있으며 신약개발시간 단축 및 비용 절감에 기여할 것으로 여겨진다.

• 대한한의학방제학회지
• /
• 제25권2호
• /
• pp.271-302
• /
• 2017

Objectives : Jakyakgamcho-tang has been used to treat muscular tension, spasm and pain. On this study, new clinical uses of Jakyakgamcho-tang were confirmed and the other pharmacological results were summarized by analysing trends of modern experimental studies and clinical studies. Methods : Papers related to Jakyakgamcho-tang were searched on PUBMED, RISS, and National Assembly Library, and classified by categories and effects of clinical application and a variety of experiment around abstract. Also, figures were used for sketching out a timeline of expressing when these papers were read and core research content was described as a digest for identifying research trends. Results : Until today, there are 104 researches about the antispasmodic, analgesic, anti-inflammatory effects of Jakyakgamcho-tang. In total, 91 papers were analyzed in this study. In matter of subject, researches on the antispasmodic effects were 17 cases, researches on the analgesic effects were 14 cases, researches on gynecological therapeutics were 14 cases, researches on pharmacokinetics were 12 cases, researches on the constituent identification were 7 cases, studies about constituents efficacy were 6 cases, studies about interactions with drugs were 6 cases. Conclusion : The traditional use of Jakyakgamcho-tang on muscle tension, spasm and pain has proven to have effects through the experimental evidences. Other effects of Jakyakgamcho-tang such as gynecological therapeutics, anti-inflammatory effects, are now emerging as a new area in clinical use. Futhermore as an auxiliary treatment, Jakyakgamcho-tang is a good alternative for muscle cramps during maintenance of hemodialysis, myalgia or arthralgia induced by anticancer drugs, amenorrhea induced by neuroleptics.

• 대한한의학방제학회지
• /
• 제20권2호
• /
• pp.187-197
• /
• 2012

Objectives : The purpose of this study is to find a reasonable solution to a current status of drug classification between the drugs of western conventional (allopathic) medicine and Korean medicine. A clear and distinct concept on the drugs of allopathic medicine and Korean medicine based on reasonable concepts and broad consensus is a pressing issue in Korea, and will facilitate the development of herbal medicinal products and pharmaceutical industry. Methods : Considering the issue of drug classification from domestic and international regulations, we reviewed the current Drug Law of Korea and China, Guidance for Industry, Botanical Drug Products of USA, Directive 2004/24/EC of the European parliament and of the council. Results : In Korea, the drug classification of allopathic medicine and Korean medicine is quite vague even though differential licensure system is enforced for the clinicians of allopathic medicine and Korean medicine field. According to the definition in the Drug Law, the scope of Korean medicine drug is so broad that even a drug made of single-compound material, as well as herbal extract of crude mixture, is regarded as a drug of Korean medicine, as long as the material may be separated from medicinal herbs, animal tissues, or mineral resources. Only new compound not found in natural resources are outside of the scope of Korean medicine drug. In USA and EU, medicinal products manufactured from herbs are approved by separate regulations for the herbs with special waivers. In China, the category of new medicine and the definition of allopathic medicine and traditional chinese medicine are clearly specified and classified. Conclusions : As medicines are validated therapeutic materials for efficacy and toxicity, we suggest that generally the concept of conventional medicines is based on a single compound that has been synthesized and individually validated and that of Korean medicines is based on a compound extracted from natural materials or a complex of compounds that has been validated as a whole in its totality.

• 약학회지
• /
• 제56권4호
• /
• pp.240-247
• /
• 2012

Sabaek-san has been used for the treatment of inflammatory diseases derived from the cold with high fever, cough, and lung dysfunction in Korea and China. There is no study for the comparison between different solvent extracts of Sabaek-san. We made two samples, one is Sabaek-san water extract (SBSW) and the other is Sabaek-san 30% EtOH extract (SBSE). Both extracts inhibited inducible nitric oxide synthase(iNOS) protein, reduced iNOS-derived nitric oxide (NO) production in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. Also, they reduced tumor necrosis factor-${\alpha}$ (TNF-${\alpha}$) and interleukin-$1{\beta}$ (IL-$1{\beta}$) production. These anti-inflammatory effects caused by induction of heme oxygenase (HO)-1. HO-1 enzyme plays an important role of cellular anti-oxidant and anti-inflammatory systems. The induction of HO-1 is primarily regulated at the transcriptional level, and its induction by various inducers is related to the nuclear transcription factor-E2-related factor 2 (Nrf2). However, it is worth taking note that SBSE has more powerful anti-inflammatory effects than SBSW. In this study we suggest that different solvent extraction makes different therapeutic actions.

• 약학회지
• /
• 제58권2호
• /
• pp.112-124
• /
• 2014

This study aimed to develop a regulation system for off-label drug use to secure the safe use of marketed drugs. We searched governmental documents for national and global regulating systems of off-label drug uses and a body of academic literature to explore current regulating trends. We included European Union, United Kingdom, United States of America, Australia and Japan, and critically reviewed the regulation of off-label drug use in four issues, which were a regulatory structure, safety control before and after off-label use, and information management. The findings of the present investigation called for several measures in off-label drug uses: enhancing prescribers' self-regulation, providing up-to-date information to prescribers for evidence-based practice and to patients for their informed consent, making evidence with scientific rigor, building an official registering process for off-label use in good quality and extending the role of pharmaceutical industry in pharmacovigilance. At last, we proposed a new system so as to regulate and evaluate off-label drug uses both at national and institutional level. In the new system, we suggested a clear-cut definition for clinical evidence that applicants would submit. We newly introduced an official 'Off-Label Drug Use Report' to evaluate the safety and clinical efficacy of a given off-label drug use. In addition, we developed an algorism of the regulation of off-label drug use within an institution to help set up the culture of evidence-based practices in off-label drug uses.

• Biomolecules & Therapeutics
• /
• 제19권4호
• /
• pp.419-424
• /
• 2011

Galla Rhois and its components are known to possess anti-infl ammatory properties. In the present study, we prepared equilibrium mixture of ethyl m-digallate and ethyl p-digallate isomers (EDG) from Galla Rhois and examined its effect on nitric oxide (NO) production in murine macrophage cell line. Treatment of RAW264.7 macrophages with EDG signifi cantly inhibited NO production and inducible nitric oxide synthase (iNOS) expression stimulated by LPS, as assessed by Western blot and quantitative RT-PCR analyses. We also demonstrated that EDG treatment led to an increase in heme oxygenase-1 (HO-1) mRNA and protein expression. EDG treatment also enhanced expression level of nuclear factor-erythroid 2-related factor 2 (Nrf2) in nucleus, which is critical for transcriptional induction of HO-1. Treatment with SnPP (tin protoporphyrin IX), a selective HO-1 inhibitor, reversed EDG-mediated inhibition of nitrite production, suggesting that HO-1 plays an important role in the suppression of NO production by EDG. Taken together, these results indicate that EDG isolated from Galla Rhois suppresses LPS-stimulated NO production in RAW 264.7 macrophages via HO-1 induction.

• 한국임상약학회지
• /
• 제33권2호
• /
• pp.86-96
• /
• 2023

Background: Using KIDS-KAERS database (KIDS-KD) from 2016 to 2020, the aim is to investigate signals of adverse events of alpha-adrenoceptor antagonists and to present adverse events that are not included in the precautions for use when marketing approval. Methods: This study was conducted by disproportionality analysis. Data mining analysis was performed to detect signals of alpha-adrenoceptor antagonists, such as terazosin, doxazosin, alfuzosin, silodosin, and tamsulosin. The signal was defined by three criteria as proportional reporting ratio (PRR), reporting odds ratio (ROR), and information component (IC). Detected signals were compared with product labeling and the European Medicines Agency-Important Medical Events list. Results: Out of the total number of 408,077 reports for adverse events, 6,750 cases were reported as adverse events of alpha-adrenoceptor antagonists. Dizziness, mouth dryness, hypotension postural, and oedema peripheral are identified as common adverse events of five alpha-adrenoceptor antagonists and are typically listed on drug labels. However, new signals were detected for pneumonia, chronic obstructive airway disease, eye diseases such as glaucoma and cataracts, fracture, and ileus of tamsulosin that were not previously listed on the drug labels in Korea. Conclusions: This study identified signals related to adverse drug reactions of alpha-adrenoceptor antagonists and presented serious adverse events, suggesting new adverse reactions to be aware of when using alpha-adrenoceptor antagonists.

• Bulletin of the Korean Chemical Society
• /
• 제32권11호
• /
• pp.3996-4000
• /
• 2011

In an attempt to find a new class of anti microbial agents, a series of thiazolidinone and their 5-arylidene derivatives containing 4-(4-methyl benzamido)-benzoyl moiety were synthesized via the reaction of benzocaine with appropriate chemical reagents. These compounds were screened for their antibacterial activity against Gram-positive bacteria (Bacillus subtilis and Bacillus thuringiensis), Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa) and antifungal activity against Botrytis fabae, Fusarium oxysporan and Candida albicans. On the other hand the synthesized compounds were also screened for their anti tubercular activity. IR, $^1H$ NMR, $^{13}C$ NMR and MS spectral analyses established the structures of the newly synthesized compounds. The results revealed that some of these compounds have shown promising antimicrobial and anti tubercular activity in comparison with standard drugs.

• 한국진공학회:학술대회논문집
• /
• 한국진공학회 2016년도 제50회 동계 정기학술대회 초록집
• /
• pp.78-78
• /
• 2016

For the past three decades, extensive research has been performed in the surface design of new polymers for a variety of medical applications. Great progress in therapeutics and diagnostics can be attributed to these scientific advances in biomedical polymers. A variety of bioinert materials or bioactive materials using drugs, cells, and growth factors are widely utilized for the implants, devices and tissue regeneration. These materials provide an improved biocompatible materials to host, to significantly decrease or increase the host/tissue/blood response to the foreign materials. In the future, biomaterials will play a different role in modern therapeutics. New materials will be tailored to interact more on a protein and cellular level to achieve high degree of biocompatibility, biospecificity and bioacitivity. In this presentation, various biocompatible materials based on surface/bulk engineering will be demonstrated, which can be utilized as therapeutics implants and therapeutic vehicles for biologically active molecules such as cell, protein /peptide and gene.

• 대한의용생체공학회:의공학회지
• /
• 제30권1호
• /
• pp.1-9
• /
• 2009

Many types of small animal imaging modalities, like micro-CT, micro-PET, and micro-SPECT, have been recently developed worldwide. Small animal imaging systems are now recognized as indispensable tools to validate efficacy and safety of new drugs or new therapeutic methods using the animal disease models. With increasing demands for small animal imaging in biomedical research, multimodal small animal imaging systems, like micro-PET/CT or micro PET/MRI, are now also being developed. Small animal imaging with spatial resolution and sensitivity comparable to human imaging is quite challenging since laboratory small animals are much smaller than human beings. Research activities in Korea on small animal imaging systems are reviewed in this paper. In the field of micro-CT and micro-PET, many world-class technologies have been developed successfully in Korea. It is expected that the developed animal imaging system technologies can be used in the development of clinical imaging systems in Korea in the near future.